APA (7th ed.) Citation

N, M., CM, A., J, S., KJ, T., KA, L., WA, R., . . . YG, S. (2020). Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers, 12(8), . https://doi.org/10.3390/cancers12082182

Chicago Style (17th ed.) Citation

N, Mukherjee, et al. "Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma." Cancers 12, no. 8 (2020). https://doi.org/10.3390/cancers12082182.

MLA (9th ed.) Citation

N, Mukherjee, et al. "Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma." Cancers, vol. 12, no. 8, 2020, https://doi.org/10.3390/cancers12082182.